The Roles of the Charlson Comorbidity Index and Time to First Antibiotic Dose as Predictors of Outcome in Pneumococcal Community-Acquired Pneumonia

Lung. 2016 Oct;194(5):769-75. doi: 10.1007/s00408-016-9922-z. Epub 2016 Jul 12.

Abstract

Purpose: In this retrospective study, we aimed to investigate the role of comorbidities using the Charlson comorbidity index (CCI) and time to first antibiotic dose (TFAD) in patients with pneumococcal community-acquired pneumonia (PCAP).

Methods: All consecutive ER admissions with PCAP who were hospitalized in the University Hospital, Zurich between 2006 and 2012 were included. The primary outcome was to determine possible determinants of all-cause in-hospital mortality (ACIHM). The second endpoint was to detect risk factors for adverse events (AEs) and determinants of length of stay (LOS).

Results: 108 subjects (mean age 57.6 years) were included. The median (IQR) CCI was 4 (1, 8). The median (IQR) TFAD was 210 (150, 280) min. ACIHM was 6.5 % (7/108), and median (IQR) LOS was 9 (6, 14) days. PCAP-related AEs were observed in 57 cases (52.8 %). In the multivariable analysis, neither CCI nor TFAD was associated with the outcome measures. Pneumonia severity index (PSI) was the only statistically significant predictor of ACIHM (HR 1.31/10 point increase, 95 % CI 1.12-1.53, p = 0.001) and AE rate (OR 1.31, 95 % CI 1.15-1.50, p < 0.001).

Conclusions: In this study including comparatively young patients with rather mild disease severity, we found no strong evidence supporting that CCI or TFAD influenced short-term outcome measures of PCAP. Yet, pneumonia severity appears to be the most important factor for the outcome.

Keywords: Comorbidity; Pneumococcal community-acquired pneumonia; Pneumonia severity index; Short-term outcome; Time to first antibiotic dose.

MeSH terms

  • Adult
  • Aged
  • Anti-Bacterial Agents / administration & dosage
  • Community-Acquired Infections / complications
  • Community-Acquired Infections / drug therapy
  • Community-Acquired Infections / mortality*
  • Comorbidity*
  • Drug Therapy, Combination
  • Female
  • Hospital Mortality
  • Humans
  • Length of Stay
  • Male
  • Middle Aged
  • Pneumonia, Pneumococcal / complications
  • Pneumonia, Pneumococcal / drug therapy
  • Pneumonia, Pneumococcal / mortality*
  • Risk Factors
  • Severity of Illness Index*
  • Switzerland / epidemiology
  • Time-to-Treatment*

Substances

  • Anti-Bacterial Agents